{{Rsnum
|rsid=3738579
|Gene=RNASEL
|Chromosome=1
|position=182586901
|Orientation=minus
|GMAF=0.2392
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=RNASEL
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 12.4 | 49.6 | 38.1
| HCB | 5.1 | 35.8 | 59.1
| JPT | 6.2 | 23.9 | 69.9
| YRI | 0.0 | 14.3 | 85.7
| ASW | 0.0 | 22.8 | 77.2
| CHB | 5.1 | 35.8 | 59.1
| CHD | 3.7 | 31.2 | 65.1
| GIH | 13.9 | 46.5 | 39.6
| LWK | 0.0 | 3.6 | 96.4
| MEX | 3.4 | 27.6 | 69.0
| MKK | 0.6 | 20.5 | 78.8
| TSI | 13.7 | 43.1 | 43.1
| HapMapRevision=28
}}[[rs3738579]] represents a SNP in the 5' UTR region upstream of the [[RNASEL]] gene. 

A study of patients diagnosed with carcinoma of the uterine cervix, head and neck squamous cell carcinomas (HNSCC), and [[breast cancer]] found 1.5x-2x increased risk for all three cancer types for the [[rs3738579]](T;T) genotype, while finding decreased risk (0.5x) for [[rs3738579]](C;T) heterozygotes. [[rs3738579]](C;C) homozygotes had 0.6x less risk for cervical cancer but increased risk for HNSCC (1.4x) and breast cancer (1.8x).{{PMID|18575592|OA=1
}} 

Although statistics were not reported per genotype, a combination of data from all three cancer forms over all genotypes provided strong statistical evidence for [[rs3738579]] as a [[cancer]] marker, with a p-value of 4.43Ã—10eâˆ’5.{{PMID|18575592|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}